While the cause of increased SAEs and exacerbations due to BIIL 284 BS is unknown , the outcome of this trial provides a cautionary tale for the administration of potent anti-inflammatory compounds to individuals with chronic infections , as the potential to significantly suppress the inflammatory response may increase the risk of infection-related adverse events .